In short
Clinical trials investigating "Amoxicillin Trihydrate" are studying how it performs in different patient groups and diseases. These studies look at outcomes such as treatment success, infection control, and safety in children, adults, and special patient groups. The trials include several phase 3 studies and focus on real-world clinical questions.
Key points
- Clinical trials of Amoxicillin Trihydrate are being done in many different patient groups, not just one disease. The studies include children with pneumonia, people with penicillin allergy, patients with infective endocarditis, diabetic foot osteomyelitis, perianal abscess, and adults after CAR-T therapy. Most trials are Phase 3 studies, which means they are testing how well the treatment or strategy works in larger groups. The main outcomes include treatment failure, infection recurrence, bone loss, fistula formation, and major heart or brain events. Several studies compare Amoxicillin Trihydrate with other antibiotic strategies or with placebo. One study also looks at whether shorter treatment can work as well as longer treatment in children with pneumonia.
Clinical trial overview
Across the source data, Amoxicillin Trihydrate is being studied in several interventional trials, mostly in Phase 3 settings. These trials ask practical questions about whether different antibiotic strategies work better, work as well as another approach, or help prevent later problems.
The studies include children, healthy adults, people with penicillin allergy, and patients with serious infections or complex medical conditions.
Trials in children with pneumonia
One major study, SPARE, is testing Amoxicillin Trihydrate in children with community-acquired alveolar pneumonia, which means pneumonia caught outside the hospital. The trial includes children between 3 and 59 months of age and compares shorter antibiotic treatment with longer treatment plans.
The main endpoint is therapeutic failure at day 7, which includes a need to change antibiotics, restart or continue antibiotics after day 7, or hospitalization or death linked to worsening pneumonia. The study is designed to show non-inferiority, meaning the shorter treatment should not be meaningfully worse than the longer one.
A second pediatric study, the NAPIC Study, looks at preschool children with lower respiratory tract infection and compares amoxicillin with placebo. Its main outcome is therapy failure by 21 days after treatment start.
Trials on infection prevention and allergy testing
The PROSPECTOR 2 trial studies people with penicillin allergy and compares a prolonged oral penicillin challenge with a single-dose challenge to find out who truly has an immune-mediated allergy. The primary outcome is a positive oral challenge, meaning an immune reaction up to day 7 after the first test dose, judged by an independent blinded panel.
The PREV-CART study includes young adults and adults aged 16 to 80 who have B-cell acute lymphoblastic leukemia or B-cell lymphoma and have been treated with CAR-T cells. It compares immunoglobulin replacement therapy with antibiotic prophylaxis, which means preventive antibiotic treatment, and includes Amoxicillin Trihydrate among the listed medicines.
The main endpoint is a composite outcome of recurrent infections or severe infection requiring hospitalization within 12 months after randomization.
Trials after surgery and dental procedures
One trial studies patients after surgical drainage of a perianal abscess, which is a painful pocket of infection near the anus. The goal is to see whether antibiotic therapy after surgery can prevent the later development of an anal fistula, an abnormal tunnel that can form after infection.
Another study looks at healthy patients undergoing dental implant surgery and compares different antibiotic protocols that include amoxicillin by mouth. The main endpoint is mean bone loss, which is used to judge how well the tissue around the implant heals.
Trials in serious infections and heart disease
The ROSIE study focuses on infective endocarditis, a serious infection of the heart lining or valves. It tests whether a standardized local protocol for partial oral consolidation therapy is non-inferior, meaning not worse than the comparison approach by more than an allowed margin.
The main endpoint is composite clinical success at 6 months, defined as no death from any cause, no unplanned heart surgery, no embolic events, and no recurrent bacteremia, which means bacteria returning in the blood.
The Antibiotic Treatment Trial in Acute Coronary Syndrome includes patients with NSTEMI, STEMI, or coronary artery disease. It studies whether antibiotic treatment can reduce major adverse cardiac and cerebrovascular events over 12 months.
Main endpoints and what they mean
The trials use different endpoints depending on the condition being studied. Common outcomes include treatment failure, infection recurrence, bone loss, fistula formation, and serious clinical events such as death or stroke.
Some trials measure a single main event, while others use a composite outcome, which combines several important events into one result.
Who can participate
Participation depends on the specific trial and diagnosis. The source data show trials for young children with pneumonia, healthy adults having dental implant surgery, people with penicillin allergy, adults with infective endocarditis, patients with diabetic foot osteomyelitis, and adults after CAR-T treatment.
Several studies are authorised and enrolling large groups, which suggests active research on how Amoxicillin Trihydrate may fit into different treatment strategies.